4D Medical faces record short pressure as institutional selling accelerates.

4D Medical faces record short pressure as institutional selling accelerates. The lung imaging medtech company's share price has collapsed forty percent in one month, falling from its April peak of six dollars eighty cents to three dollars fifty cents. Short sellers now hold seven percent of shares on issue while major institutions including JP Morgan, Morgan Stanley, and UBS Securities have dumped over one hundred twenty million dollars worth of stock. Despite securing contracts and partnerships with Stanford, the fundamental issue remains clear: 4DX generates minimal revenue yet carries a two billion dollar market cap. Commonwealth Securities and CMC Markets bought shares during the selloff, but supply continues overwhelming demand. The company's latest announcement about lung surgery applications failed to restore investor confidence in its valuation.